Vanda Pharmaceuticals Stock
Vanda Pharmaceuticals Stock
Heavy losses for Vanda Pharmaceuticals today as the stock fell by -€0.300 (-5.310%).
With 13 Buy predictions and not the single Sell prediction the community is currently very high on Vanda Pharmaceuticals.
With a target price of 17 € there is potential for a 217.76% increase which would mean more than doubling the current price of 5.35 € for Vanda Pharmaceuticals.
So far the community has only identified positive things for Vanda Pharmaceuticals stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Vanda Pharmaceuticals in the next few years
Pros
?
B****
?
S********** s********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Vanda Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Vanda Pharmaceuticals | -5.310% | 15.302% | 40.052% | 19.955% | 16.812% | -23.571% | -49.528% |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
Comments
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Show more
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Show more
Ratings data for VNDA provided by MarketBeat
Vanda Pharmaceuticals (NASDAQ:VNDA) had its price target lowered by analysts at Cantor Fitzgerald from $13.00 to $11.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for VNDA provided by MarketBeat